การป้องกันการติดเชื้อในการใช้เลือดและส่วนประกอบของเลือด
Keywords:
-Abstract
-
Downloads
References
American Association of Blood Banks. Technical Manual. 19th ed. Bethesda, MD: AABB; 2017.
COVID-19 Coronavirus Pandemic-WorldOMeter. Available from: https://www.worldometers.info/coronavirus/. Accessed Jun 15, 2020.
Leblanc JF, Germain M, Delage G, Brien SO, Drews SJ, Lewin A. Risk of transmission of severe acute respiratory syndrome coronavirus 2 by transfusion: a literature review. Transfusion. 2020;60:3046-54.
Armstrong B. Blood collection. VOXS. 2008;3:123-36.
Liumbruno GM, Catalano L, Piccinini V, Pupella S, Grazzini G. Reduction of the risk of bacterial contamination of blood components
through diversion of the first part of the donation of blood and blood components. Blood Transfus. 2009;7:86-93.
Kakaiya R, Aronson CA, Julleis J. Whole blood collection and component processing. In: Roback JD, Combs MR, Grossman BJ, Hillyer CD, editors. Technical manual. 16thed. Bethesda, MD: American Association of Blood Banks; 2008. p. 192.
Patel TG, Shukla RV, Gupte SC. Impact of donor arm cleaning with different aseptic solutions for prevention of contamination in blood bags. Indian J Hematol Blood Transfus. 2013;29:17-20.
Shah S, Mehta NA, Jadhav SG. Prospective evaluation of 2% (w/v) alcoholic chlorhexidine gluconate as an antiseptic agent for blood donor arm preparation. Asian J Transfus Sci. 2014;8:92-5.
Rao PL, Strausbaugh LJ, Liedtke LA, Srinivasan A, Kuehnert MJ. Bacterial infections associated with blood transfusion: experience and perspective of infectious diseases consultants. Transfusion. 2007;47:1206-11.
Visconti MR, Pennington J, Garner SF, Allain JP, Williamson LM. Assessment of removal of human cytomegalovirus from blood components by leukocyte depletion filters using real-time quantitative PCR. Blood. 2004;103:1137-9.
Thibault L, Beausejour A, Grandmont MJ, Lemieux R, Leblanc JF. Characterization of blood components prepared from whole-blood donations after a 24-hour hold with the platelet-rich plasma method. Transfusion. 2006;46:1292-9.
Pietersz RNI. Pooled platelet concentrates: an alternative to single donor apheresis platelets? Transfus Apher Sci. 2009;41:115-9.
Schmidt M. Bacterial contamination of blood products. VOXS. 2013;8:177-80.
Fong IW. Blood transfusion-associated infections in the twenty-first century: new challenges. Current Trends and Concerns in Infectious Diseases. 2020:191-215.
Brecher ME, Hay SN. Bacterial contamination of blood components. Clin Microbial Rev. 2005;18:195-204.
Fang CT, Chambers LA, Kennedy J, Strupp A, Fucci MC, Janas JA, et al. Detection of bacterial contamination in apheresis platelet products: American Red Cross experience, 2004. Transfusion. 2005;45:1845-52.
Bihl F, Castelli D, Marincola F, Dodd RY, Brander C. Transfusion-transmitted infections. J Transl Med. 2007;5:25. doi: 10.1186/1479-5876-5-25.
Hogman CF, Engstrand L. Serious bacterial complications from blood components-how do they occur? Transfus Med. 1998;8:1-3.
Wagner SJ, Robinette D, Friedman LI, Miripol J. Diversion of initial blood flow to prevent whole-blood contamination by skin surface bacteria: an in vitro model. Transfusion. 2000;40:335-8.
Sagara Y, Nakamura H, Yamamoto M, Ezaki T, Koga T, Shimamura M, et al. Estimation of the window period of human T-cell leukemia virus type I and 2 tests by a lookback study of seroconverters among Japanese voluntary blood donors. Transfusion. 2021;61:484-93.
Mardani A. Prevention strategies of transfusion-transmitted parasitic infections (TTPIs): strengths and challenges of current approaches, and evaluation of the strategies implemented in Iran. Parasite Epidemiol Control. 2020;9:e00141. doi: 10.1016/j.parepi.2020.e00141.
Singh G, Sehgal R. Transfusion-transmitted parasitic infections. Asian J Transfus Sci. 2010;4:73-7.
Lipson SM, Shepp DH, Match ME, Axelrod FB, Whitbread JA. Cytomegalovirus infectivity in whole blood following leukocyte reduction by filtration. Am J Clin Pathol. 2001;116:52-5.
Pehta JC. Clinical studies with solvent detergent-treated products. Transfus Med Rev. 1996;10:303-11.
Chuansumrit A, Isarangkura P, Chantanakajornfung A, Kuhathong K, Pintadit P, Jitpraphai C, et al. The efficacy and safety of lyophilized cryoprecipitate in Hemophilia A. J Med Assoc Thai. 1999;82:69-73.
Politis C, Kavallierou L, Hantziara S, Katsea P, Triantaphylou V, Richardson C, et al. Quality and safety of fresh-frozen plasma inactivated and leucoreduced with the Theraflex methylene blue system including the Blueflex filter: 5 years’ experience. Vox Sang. 2007;92:319-26.
Garwood M, Cardigan RA, Drummond O, Hornsey V, Turner CP, Young D, et al. The effect of methylene blue photoinactivation and methylene blue removal on the quality of fresh-frozen plasma. Transfusion. 2003;43:1238-47.
Schlenke P, Hervig T, Isola H, Wieset ML, Kientz D, Pinkoski L, et al. Photochemical of plasma with amotosalen and UVA light: process validation in three European blood centers. Transfusion. 2008;48:697-705.
Marschner S, Goodrich R, Pathogen reduction technology treatment
of platelets, plasma and whole blood using riboflavin and UV light. Transfus Med Hemother. 2011;38:8-18.
Janetzko K, Bugert P. Pathogen reduction in blood products: What’s behind these techniques?. Transfus Med Hemother. 2011;38:5-6.
Ragan I, Hartson L, Pidcoke H, Bowen R, Goodrich R. Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light. PLoS One. 2020;15:e0233947. doi: 10.1371/journal.pone.0233947.
Armstrong VA. Quality assurance in blood banking: the basis for safety. VOXS. 2009;4:281-5.
